A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab

Fragkou, Paraskevi C.; Souli, Maria; Theochari, Maria; Kontopoulou, Christina; Loukides, Stelios; Koumarianou, Anna

doi:10.33393/dti.2016.1420

Cited by 16 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Airspace disease may manifest as either consolidative or ground-glass opacities or a combination of both, frequently depicted on air bronchograms with or without a component of bronchial dilatation. A circumferential consolidative opacity surrounding an interior area of ground-glass attenuation (ie, reversed halo or atoll sign), a relatively specific marker for OP in the nontreatment setting, has also been reported in ICI therapy-related pneumonitis (32). Airspace disease can also be migratory, changing location or configuration over time (33).…”

Section: Op Patternmentioning

confidence: 99%

Immune Checkpoint Inhibitor Therapy–related Pneumonitis: Patterns and Management

et al. 2019

View full text Add to dashboard Cite

Abbreviations: AIP = acute interstitial pneumonia, ARDS = acute respiratory distress syndrome, CTCAE = Common Terminology Criteria for Adverse Events, CTLA-4 = cytotoxic T-lymphocyte antigen-4, HP = hypersensitivity pneumonitis, ICI = immune checkpoint inhibitor, irAE = immune-related adverse event, NSIP = nonspecific interstitial pneumonia, OP = organizing pneumonia, PD-1 = programmed cell death protein 1, PD-L1 = programmed cell death ligand 1

show abstract

Section: Op Patternmentioning

confidence: 99%

Immune Checkpoint Inhibitor Therapy–related Pneumonitis: Patterns and Management

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The COP pattern typically manifests with multifocal consolidation and GGOs in a predominantly peripheral distribution ( Fig 5). The hypersensitivity pneumonitis pattern manifests with diffuse GGOs and centrilobular nodularities and may also include air trapping ( Fig 6) (7,21,(23)(24)(25)(26)(27)(28).…”

Section: Teaching Pointsmentioning

confidence: 99%

Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care

et al. 2017

View full text Add to dashboard Cite

Recent advances in understanding the molecular mechanisms of cancer have opened a new era of precision medicine for cancer treatment. Precision cancer therapies target specific molecules that are responsible for cancer development and progression, and they achieve marked treatment benefits in specific cohorts of patients. However, these therapies are also associated with a variety of complications that are often unique to specific groups of anticancer agents. The rapidly increasing use of immune checkpoint inhibitors in the treatment of various advanced malignancies has brought new challenges in diagnosing and monitoring a unique set of toxic effects termed immune-related adverse events. Familiarity with cutting-edge cancer treatment approaches and awareness of the emerging complications from novel therapies are essential for radiologists, who play a key role in the care of patients with cancer. This article provides a comprehensive review of the thoracic complications of precision cancer therapies, describes their imaging features and clinical characteristics, and discusses the role of radiologists in the diagnosis and monitoring of these entities. The authors also address the molecular mechanisms of anticancer agents that relate to thoracic complications and emphasize emerging challenges in novel cancer therapies. This article is designed to serve as a practical reference guide for day-to-day practice for radiologists in the era of precision cancer medicine. RSNA, 2017.

show abstract

“…More recently, a case of OP was described in a melanoma patient treated with nivolumab [ 11 ]. Only two cases of pulmonary side effects with pembrolizumab have thus far been described: one case of OP occurring after four infusions and one case of mediastinal granulomatosis [ 13 – 15 ]. In clinical trials of pembrolizumab and nivolumab, the majority of pneumonitis cases have been reported as mild to moderate in severity, but one death has occurred [ 2 – 4 , 10 ].…”

mentioning

confidence: 99%

Pembrolizumab-induced pneumonitis

et al. 2017

View full text Add to dashboard Cite

Immune checkpoint inhibitors are promising new therapies for advanced cancers. In particular, antibodies against programmed cell death 1 (PD-1), such as nivolumab and pembrolizumab, increase anti-tumour T cell responses by blocking the interaction between PD-1 on T cells and its ligand PD-L1 on cancer cells [1]. Enhanced T-cell responses resulting from checkpoint inhibition can lead to an unusual spectrum of side effects called immune-related adverse events, which involve numerous organs, particularly the skin, liver, and gastrointestinal and endocrine systems [2–11]. Pneumonitis is a potentially lethal side effect of immune checkpoint inhibition, occurring in 1–5% of patients enrolled in trials [2–11]. However, little is known about the clinical and radiological features of checkpoint inhibitor-induced lung disease. Here, we report three cases of pembrolizumab-induced acute interstitial lung disease (ILD). The medical data of the patients presented below were collected in accordance with French regulations, none of which was opposed to their uses.

show abstract

A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab

Cited by 16 publications

References 18 publications

Immune Checkpoint Inhibitor Therapy–related Pneumonitis: Patterns and Management

Immune Checkpoint Inhibitor Therapy–related Pneumonitis: Patterns and Management

Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care

Pembrolizumab-induced pneumonitis

Contact Info

Product

Resources

About